- Report
- February 2025
- 233 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- January 2025
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- April 2024
- 496 Pages
Global
From €6650EUR$6,995USD£5,587GBP
- Report
- March 2025
- 1048 Pages
Global
From €4562EUR$4,799USD£3,833GBP
- Report
- March 2025
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 192 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 196 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- August 2024
- 200 Pages
Global
From €2177EUR$2,290USD£1,829GBP
- Report
- October 2024
- 192 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- July 2024
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- July 2024
- 303 Pages
Global
From €3327EUR$3,500USD£2,795GBP
€4753EUR$5,000USD£3,993GBP
- Report
- February 2025
- 144 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- August 2024
- 150 Pages
Global
From €2651EUR$2,789USD£2,227GBP
- Report
- July 2024
- 180 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- February 2025
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- February 2025
- 180 Pages
Global
From €4278EUR$4,500USD£3,594GBP

Cancer Monoclonal Antibodies (mAbs) are a type of oncology drug used to treat cancer. They are a type of biologic therapy, which means they are made from living cells. mAbs are designed to target specific proteins on cancer cells, which can help to slow or stop the growth of the cancer. They can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. mAbs can be used to treat a variety of cancers, including breast, lung, and colorectal cancer.
The Cancer Monoclonal Antibodies market is a rapidly growing segment of the oncology drugs market. mAbs are becoming increasingly popular due to their ability to target specific proteins on cancer cells, which can help to reduce side effects and improve outcomes. Additionally, mAbs are often more cost-effective than other treatments, making them attractive to healthcare providers.
Some of the major companies in the Cancer Monoclonal Antibodies market include Roche, Merck, Bristol-Myers Squibb, Amgen, and Novartis. Show Less Read more